Metabolism studies of biopharmaceuticals

AB SCIEX and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.

This project is focused on developing a standardized testing methodology based on an approach pioneered by scientists at the University of Melbourne on the AB SCIEX QTRAP 5500 system. The approach would allow scientists to follow the fate of the breakdown of protein-based drugs in vivo. This could help drug discovery scientists better determine the effectiveness and safety of peptide and protein therapeutic agents that are advanced through regulatory processes and ultimately sold on the consumer market.

“Targeting the unknown breakdown products of a biologic without knowing what they are is revolutionary in the biopharmaceutical industry. The technology we are developing with AB SCIEX will give scientists the unique ability to produce metabolism profiles for peptide and protein drugs that the industry simply cannot do right now. This is essential for advancing an increasing number of biopharma drugs to market,” said Anthony Purcell, associate professor, senior research fellow and a principal investigator at the department of biochemistry and molecular biology, the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne.

For more information visit www.absciex.com